Two Sigma Advisers LP Has $59.79 Million Stock Holdings in Natera, Inc. (NASDAQ:NTRA)

Two Sigma Advisers LP boosted its holdings in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 19.8% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 377,700 shares of the medical research company's stock after acquiring an additional 62,400 shares during the period. Two Sigma Advisers LP owned 0.29% of Natera worth $59,790,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the business. Tairen Capital Ltd acquired a new stake in Natera during the 4th quarter worth $1,694,000. Teza Capital Management LLC acquired a new stake in Natera during the 4th quarter worth $221,000. True Wealth Design LLC grew its holdings in Natera by 39.6% during the 4th quarter. True Wealth Design LLC now owns 631 shares of the medical research company's stock worth $100,000 after acquiring an additional 179 shares during the period. Shell Asset Management Co. acquired a new stake in Natera during the 4th quarter worth $180,000. Finally, Silvercrest Asset Management Group LLC grew its holdings in Natera by 3.6% during the 4th quarter. Silvercrest Asset Management Group LLC now owns 2,812 shares of the medical research company's stock worth $445,000 after acquiring an additional 98 shares during the period. Institutional investors and hedge funds own 99.90% of the company's stock.

Analyst Ratings Changes

A number of analysts have commented on the stock. BTIG Research reaffirmed a "buy" rating on shares of Natera in a report on Friday, February 28th. Canaccord Genuity Group reissued a "buy" rating and set a $180.00 price target on shares of Natera in a research report on Wednesday, February 26th. Wall Street Zen cut shares of Natera from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. Royal Bank of Canada assumed coverage on shares of Natera in a research report on Thursday, March 13th. They set an "outperform" rating and a $251.00 price target on the stock. Finally, Barclays lifted their price target on shares of Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a research report on Friday, May 9th. One analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $182.12.

Insiders Place Their Bets

In other Natera news, Director Gail Boxer Marcus sold 4,000 shares of the business's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $147.69, for a total transaction of $590,760.00. Following the sale, the director now directly owns 9,704 shares of the company's stock, valued at $1,433,183.76. The trade was a 29.19% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Michael Burkes Brophy sold 2,562 shares of the business's stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $138.41, for a total transaction of $354,606.42. Following the sale, the chief financial officer now directly owns 75,557 shares in the company, valued at $10,457,844.37. This trade represents a 3.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 152,436 shares of company stock valued at $22,019,079 in the last three months. 7.60% of the stock is currently owned by corporate insiders.

Natera Stock Up 0.6%

NTRA traded up $0.84 during trading on Friday, hitting $153.32. The company had a trading volume of 1,085,198 shares, compared to its average volume of 1,392,841. The company has a market capitalization of $20.94 billion, a PE ratio of -87.11 and a beta of 1.79. Natera, Inc. has a one year low of $92.14 and a one year high of $183.00. The firm's 50-day moving average price is $149.39 and its 200 day moving average price is $157.72. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.09. The business had revenue of $501.83 million for the quarter, compared to analysts' expectations of $446.68 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm's revenue was up 36.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.56) EPS. As a group, equities analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.